Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoproterenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoproterenol SCHEMBL29519146 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL29620666 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL4165 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL250806 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL3253794 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL4166 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL7627 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL4745572 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL6151626 | 0.98 | MAPT (0.97) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL3672791 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4138075-B1 | VOICE TRIGGER FOR A DIGITAL ASSISTANT | APPLE INC (US) | 2025-06-11 | — | — | EP | claimed |
| EP-4749288-A1 | COMPOSITIONS FOR DETECTING, CHARACTERIZING, AND REMOVING A BIOFILM | COSA Group GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026087899-A1 | MODULATORS OF THE GPR17 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2026-04-30 | — | — | WO | disclosed |
| EP-4720097-A1 | PEPTIDES WITH LIPOLYTIC, ANTI-LIPOGENIC, ANTIFIBROTIC AND ANTI-INFLAMMATORY ACTIVITY | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) | 2026-04-08 | — | — | EP | disclosed |
| US-20260069555-A1 | Compositions and Methods for Modulating the Effect of Beta-Blocker Activity in a Subject | UNIV DUKE (US) | 2026-03-12 | — | — | US | disclosed |
| US-12569451-B2 | Bio-inspired tissue-adhesive hydrogel patch and uses thereof | Cellartgen Inc. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20260042595-A1 | PRESSURISED DISPENSING CONTAINER | BESPAK EUROPE LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| EP-4688061-A1 | IMPROVEMENTS RELATING TO THE STOPPERING OF CONTAINERS | Bespak Europe Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688067-A1 | IMPROVEMENTS RELATING TO THE FILLING AND STOPPERING OF CONTAINERS | Bespak Europe Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688066-A1 | IMPROVEMENTS RELATING TO THE FILLING AND STOPPERING OF CONTAINERS | Bespak Europe Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| EP-3810591-B1 | PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2022-08-10 | — | — | EP | disclosed |
| US-11366114-B2 | Genetically encoded fluorescent sensors for detecting ligand bias and intracellular signaling through cAMP pathways | MONTANA MOLECULAR LLC (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022115207-A1 | METHOD FOR ATTENUATING NEUROINFLAMMATION | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2022-06-02 | — | — | WO | disclosed |
| US-11345662-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2022-05-31 | — | — | US | disclosed |
| CN-108634294-B | Stable-effect cooling agent and preparation process thereof | 珠海首力企业有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| EP-3981393-A1 | BIOMIMETIC TISSUE-ADHESIVE HYDROGEL PATCH AND USE THEREOF | Cellartgen Inc. (KR) | 2022-04-13 | — | — | EP | disclosed |
| US-11278875-B2 | Direct synthesis of metal-containing CHA zeolites | Ecovyst, Inc (US) | 2022-03-22 | — | — | US | disclosed |
| WO-2022049414-A1 | NITAZOXANIDE FOR USE TO TREAT COVID-19 | SIEGFRIED RHEIN, S.A. DE C.V. (MX) | 2022-03-10 | — | — | WO | disclosed |
| CN-114072132-A | Bionic tissue adhesive hydrogel patch and application thereof | 赛拉尔研究有限公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | ADRB2 1266/4885ADRB1 744/4885ADRB3 648/4885 |
| US-11345662-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | ADRB2 1266/4885ADRB1 744/4885ADRB3 648/4885 |
| US-20260069555-A1 | Compositions and Methods for Modulating the Effect of Beta-Blocker Activity in a Subject | ARRB1, ADRB1, ADRB3 | ADRB2 4/4885ADRB1 2/4885ADRB3 3/4885 |
| US-20260042595-A1 | PRESSURISED DISPENSING CONTAINER | VAPA, ADH1A, PDHA1 | ADRB2 866/4885ADRB1 1217/4885ADRB3 2275/4885 |
| US-12569451-B2 | Bio-inspired tissue-adhesive hydrogel patch and uses thereof | CD44, DBH, ADRB3 | ADRB2 7/4885ADRB1 10/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.